Sinus Venosus Atrial Septal Defects Medication

Updated: Dec 15, 2020
  • Author: Gary M Satou, MD, FASE; Chief Editor: Howard S Weber, MD, FSCAI  more...
  • Print

Medication Summary

Medical management is ineffective in the treatment of sinus venosus defects. The rare patient who presents in congestive heart failure can be stabilized medically with diuretics and inotropic support.


Inotropic agents

Class Summary

These agents provide myocardial support in patients with dysfunction secondary to pulmonary overcirculation from left-to-right shunting. Positive inotropic agents increase the force of contraction of the myocardium and are used to treat acute and chronic congestive heart failure (CHF). Some may also increase or decrease the heart rate (ie, positive or negative chronotropic agents), provide vasodilatation, or improve myocardial relaxation. These additional properties influence the choice of drug for specific circumstances.

Digoxin (Lanoxin)

Exerts its inotropic effects by increasing amount of intracellular calcium available during excitation-contraction coupling. One of numerous inotropic agents that can be used in infants with congenital cardiac defects. Generally used for long-term administration and is rarely drug of choice for acute management of heart failure in ICU setting.

Dopamine (Intropin)

Adrenergic agonists often are used for inotropic support in critical care setting for their rapid onset of action and rapid time to peak effect, which make them easier to titrate to effect


Loop diuretics

Class Summary

These agents are used for management of right heart failure and pulmonary edema. They promote excretion of water and electrolytes by the kidneys.

Furosemide (Lasix)

Highly effective first-line diuretic in newborns and infants. A sulfonamide derivative, it exerts its effects on the loop of Henle and distal renal tubule, inhibiting reabsorption of sodium and chloride.